|
|
Inovio Biomedical to Present at Novel Vaccines: Design & Development
By Inovio Biomedical
Publication date : Wednesday, 12 August 2009
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development
|
|  and delivery, announced today that David B. Weiner, Ph.D., Professor, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, and chairman of Inovio’s scientific advisory board, will make a presentation at Novel Vaccines: Design & Development, part of the ImVacs Immunotherapeutics & Vaccine Summit being hosted August 18th – 19th at the Renaissance Providence Hotel in Providence, RI. Dr. Weiner will make his presentation, entitled, “Development of Novel DNA Vaccines for Influenza and HIV,” on Wednesday, August 19, 2009, at 1:45 p.m.
About Inovio Biomedical Corporation
Inovio Biomedical is engaged in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses.
Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania and the National Microbiology Laboratory of the Public Health Agency of Canada. Other partners and collaborators include Merck, Tripep, University of Southampton, and HIV Vaccines Trial Network. Inovio’s product candidates and technologies are protected by an extensive global intellectual property portfolio. More information is available at
http://www.inovio.com
Want to read more?
Inovio Biomedical and NIH Vaccine Research Center
Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
MabThera receives positive opinion in Europe
|
|
